TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28686771

Group type: EXPERIMENTAL
Intervention: Clindamycin-BP 3.75% aqueous gel, once-daily for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clindamycin-BP 3.75% aqueous gel, continued treatment for a further 12 weeks for patients with ≥50% reduction in total lesion count
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clindamycin-BP 3.75% aqueous gel
Number of subjects: 20
Study: 25644134

Group type: EXPERIMENTAL
Intervention: Removable partial dentures (RPD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shortened dental arch (SDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 23400620

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (152 mg/d vitamin C and 50 mg/d vitamin E)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20849805

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17522594

Group type: EXPERIMENTAL
Intervention: BE1 +9/+9 genotype in white Americans
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: BE1 +9/-9 genotype in white Americans
Number of subjects: 228

Group type: COMPARATOR
Intervention: BE1 -9/-9 genotype in white Americans
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: BE1 +9/+9 genotype in black Americans
Number of subjects: 228

Group type: COMPARATOR
Intervention: BE1 +9/-9 and -9/-9 genotypes in black Americans
Number of subjects: 228
Study: 16565956

Group type: EXPERIMENTAL
Intervention: VBMCP and recombinant interferon alfa‐2 (INFalpha‐2)
Number of subjects: 653

Group type: COMPARATOR
Intervention: VBMCP alone
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: VBMCP and high‐dose cyclophosphamide
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: All eligible patients
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Patients who achieved a CR
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Patients with a partial response
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Patients in CR with nonclonal disease
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Patients in CR with persistent clonal disease
Number of subjects: 653
Study: 14693058

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) 3.5 g/m(2) intravenously plus rhG-CSF 5 microg x kg(‐1) x day(‐1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) 1000 mg/m(2) or 1500 mg/m(2) intravenously plus rhG-CSF 5 microg x kg(‐1) x day(‐1)
Number of subjects: 52
Study: 11075314

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (2 mg every 12 hours)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg every 12 hours)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of rosiglitazone and metformin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rosiglitazone and metformin (alone or in combination)
Number of subjects: 16
Study: 9345020

Group type: EXPERIMENTAL
Intervention: SCF plus G‐CSF
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: SCF pretreatment followed by SCF plus G‐CSF
Number of subjects: 62

Group type: COMPARATOR
Intervention: SCF pretreatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (G‐CSF alone)
Number of subjects: 62
Study: 8177925

Group type: EXPERIMENTAL
Intervention: Piracetam (2.9, 4.8, and 9.6 g Nootropil UCB)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3516510

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 100 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29747232

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 27097693

Group type: EXPERIMENTAL
Intervention: Intralesional chloroquine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Oral chloroquine
Number of subjects: 86
Study: 25230076

Group type: EXPERIMENTAL
Intervention: Air Optix Aqua Multifocal (AOAM)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PureVision Multifocal (PM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Monofocal contact lenses (Air Optix Aqua)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AOAM and PM
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All contact lenses
Number of subjects: 28
Study: 24351534

Group type: EXPERIMENTAL
Intervention: Glutamine (0.3 g/kg protein in the form of glutamine dipeptide for 10 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glutamine combined with ulinastatin (0.3 g/kg protein in the form of glutamine dipeptide for 10 days + intravenous injection of 100 kU ulinastatin every 8 hours for 7 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 60
Study: 20022651

Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 0
Study: 18156400

Group type: EXPERIMENTAL
Intervention: 7.5 g/d DHA oil (3 g DHA/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 100
Study: 15665711

Group type: EXPERIMENTAL
Intervention: MCV-4
Number of subjects: 1398

Group type: COMPARATOR
Intervention: PSV-4
Number of subjects: 1398
Study: 12620949

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) with 0.15 mL x kg(‐1) x hr(‐1) 0.2% ropivacaine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with 5 mL single bolus application of R or BS every 20 min
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PCEA with R
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ropivacaine plasma concentrations after PCEA
Number of subjects: 28
Study: 10846377

Group type: EXPERIMENTAL
Intervention: Trial Discussions condition (jurors permitted to discuss evidence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Discussions condition (jurors prohibited from discussing evidence)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial Discussions condition
Number of subjects: 0
Study: 9359638

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Direct intraperitoneal insemination (DIPI)
Number of subjects: 207
Study: 1345040

Group type: EXPERIMENTAL
Intervention: Experimental gown
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard drape
Number of subjects: 147
Study: 4004977

Group type: COMPARATOR
Intervention: Self-help education program for arthritis patients
Number of subjects: 0
Study: 28266704

Group type: EXPERIMENTAL
Intervention: EO/LP solution (Australian eucalyptus oil and Leptospermum petersonii); applied thrice with 7-day intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EO/LP solution (Australian eucalyptus oil and Leptospermum petersonii); single application
Number of subjects: 0

Group type: COMPARATOR
Intervention: P/PB mousse (pyrethrins and piperonyl butoxide); applied twice with a 7-day interval
Number of subjects: 0
Study: 27707940

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CH)
Number of subjects: 6095

Group type: COMPARATOR
Intervention: Iodine Tincture (IT)
Number of subjects: 6095
Study: 24655542

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (eight sessions over 4 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Acupuncture treatment (after a 4-week waiting period)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 76
Study: 22446143

Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Number of subjects: 97

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97

Group type: COMPARATOR
Intervention: ongoing treatment
Number of subjects: 97
Study: 20516443

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (CB)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Capecitabine, bevacizumab, and mitomycin (CBM)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 471
Study: 18929270

Group type: EXPERIMENTAL
Intervention: HGA-S (headgear-activator with stepwise mandibular advancement)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: HGA-M (headgear-activator with maximum jumping of the mandible)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: HGH-S (headgear-Herbst appliance with stepwise advancement)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Matched controls (not specified)
Number of subjects: 3
Study: 11703953

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 35
Study: 9236651

Group type: EXPERIMENTAL
Intervention: Expectant management (n = 19)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Surgical management (n = 16)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 35

Group type: COMPARATOR
Intervention: Expectant management and Surgical management
Number of subjects: 35
Study: 8220862

Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride (0.5%) moistened Kaltostat dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline moistened Kaltostat dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dry calcium alginate dressing (Kaltostat Britcair)
Number of subjects: 0
Study: 3476513

Group type: EXPERIMENTAL
Intervention: Oral rinse containing 300 micrograms/ml sanguinaria extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supragingival irrigation with dilute solutions of sanguinaria (22.5 micrograms/ml and 90 micrograms/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo oral rinse
Number of subjects: 0
Study: 29204811

Group type: EXPERIMENTAL
Intervention: GenomeCOMPASS™ report
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care summary letter
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GenomeCOMPASS™ report (after crossover)
Number of subjects: 52
Study: 29142959

Group type: EXPERIMENTAL
Intervention: HIPPO-ST
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study: 26354567

Group type: EXPERIMENTAL
Intervention: Atorvastatin (intervention group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 43
Study: 23602068

Group type: EXPERIMENTAL
Intervention: 30 mg/kg intravenous methylprednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20664583

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 18416473

Group type: EXPERIMENTAL
Intervention: Current alcohol consumption (defined as more than once of alcohol drinking per month)
Number of subjects: 3953

Group type: EXPERIMENTAL
Intervention: Current alcohol consumption
Number of subjects: 3953
Study: 16798445

Group type: COMPARATOR
Intervention: 0.2% ropivacaine (R-group)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine with fentanyl 2 microg/mL (RF-group)
Number of subjects: 198
Study: 12884990

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 10 mg and fentanyl 25 microg (upright for 15 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 15 mg (immediately positioned supine)
Number of subjects: 30
Study: 10993854

Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 1432

Group type: EXPERIMENTAL
Intervention: Quitters
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 1432
Study: 8827897

Group type: EXPERIMENTAL
Intervention: Oral vitamin K1 (N = 13)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 (N = 16)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (N = 15)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups at one-month follow-up
Number of subjects: 44
Study: 1447916

Group type: EXPERIMENTAL
Intervention: Experimental version with a pause before targeted words
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control version with normal prosody
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: CA matched group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MLU matched group
Number of subjects: 72
Study: 31331273

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27880888

Group type: EXPERIMENTAL
Intervention: Multiple hop test (MHT) for CAI subjects
Number of subjects: 51

Group type: COMPARATOR
Intervention: Uninjured controls
Number of subjects: 51
Study: 26365555

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (cholecalciferol) 100,000 IU (2.5 mg) monthly for an estimated median of 3.3 years (range 2.5‐4.2 years)
Number of subjects: 5110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 5110
Study: 24462634

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including individual education and one to three additional interventions.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 11
Study: 21637099

Group type: EXPERIMENTAL
Intervention: Simulator training to automaticity
Number of subjects: 30

Group type: COMPARATOR
Intervention: Proficiency-based training
Number of subjects: 30
Study: 19444661

Group type: EXPERIMENTAL
Intervention: Stress and coping model interventions addressing negative affect, adaptive coping, and social support
Number of subjects: 244

Group type: COMPARATOR
Intervention: Neuropsychological functioning assessment
Number of subjects: 244
Study: 18990064

Group type: EXPERIMENTAL
Intervention: Pexiganan cream (topical antimicrobial peptide)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Ofloxacin (oral fluoroquinolone antibiotic)
Number of subjects: 835
Study: 15673386

Group type: EXPERIMENTAL
Intervention: Late potential (LP) by signal-averaged ECG (SAECG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RMS40
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RMS40 < 15 microV
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: LAS40 and fQRSd
Number of subjects: 46
Study: 12637463

Group type: EXPERIMENTAL
Intervention: Bexarotene 200 mg/m²/d
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Bexarotene 500 mg/m²/d
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Tamoxifen and Bexarotene
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 145
Study: 10593328

Group type: EXPERIMENTAL
Intervention: Oral immunonutrition (an arginine‐, RNA‐, and omega3 fatty acid‐supplemented diet) for 5 days preoperatively and enteral feeding for 10 days postoperatively
Number of subjects: 154

Group type: COMPARATOR
Intervention: Isoenergetic control diet (1 L/d) for 5 days preoperatively and enteral feeding for 10 days postoperatively
Number of subjects: 154
Study: 8914685

Group type: EXPERIMENTAL
Intervention: InGaAl diode laser (670 nm, 60 mW, appr. 108 J)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-coherent monochromatic light (635 nm, 112.5 mW, appr. 202.5 J)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: He-Ne laser (632.8 nm, 10 mW, total energy appr. 9.4 J)
Number of subjects: 10
Study: 1860327

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 5 micrograms/kg.min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 10 micrograms/kg.min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at all three rates (2.5, 5, and 10 micrograms/kg.min)
Number of subjects: 8
Study: 6839635

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg a day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine 2400 mg a day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Phenytoin alone (control)
Number of subjects: 8
Study: 30422911

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs)
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Nucleoside reverse transcriptase inhibitors
Number of subjects: 861
Study: 28264870

Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PCI) in patients with early Q waves (QW)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention (PCI) in patients without early Q waves (non-QW)
Number of subjects: 515
Study: 26805558

Group type: EXPERIMENTAL
Intervention: 20 minutes post-infusion scalp cooling
Number of subjects: 134

Group type: COMPARATOR
Intervention: 45 minutes post-infusion scalp cooling
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 134
Study: 25375400

Group type: EXPERIMENTAL
Intervention: Autologous fibroblast-hyaluronic acid complex
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-adherent foam dressing (Control)
Number of subjects: 63
Study: 22516910

Group type: EXPERIMENTAL
Intervention: Nonlinear periodized resistance training (NLP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Linear periodized resistance training (LP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 20073213

Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western medicine (Yuntu recipe)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medical supportive treatment (fluid infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal control (30 women with regular pregnancy)
Number of subjects: 60
Study: 17504881

Group type: EXPERIMENTAL
Intervention: Levodopa (ON condition)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No levodopa (OFF condition)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy subjects (OFF condition)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy subjects (ON condition)
Number of subjects: 23
Study: 15140849

Group type: EXPERIMENTAL
Intervention: Interactive multimedia program
Number of subjects: 517
Study: 11453674

Group type: EXPERIMENTAL
Intervention: Perlite exposure (n=36)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Smoker perlite workers (n not specified)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Unexposed office workers (n=22)
Number of subjects: 58
Study: 9869784

Group type: EXPERIMENTAL
Intervention: PMMA intraocular lens
Number of subjects: 240

Group type: COMPARATOR
Intervention: Silicone intraocular lens
Number of subjects: 240

Group type: COMPARATOR
Intervention: Soft acrylic intraocular lens
Number of subjects: 240
Study: 8304565

Group type: EXPERIMENTAL
Intervention: 2 mg/kg pentamidine isethionate, administered in four every-other-day injections
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 3 mg/kg pentamidine isethionate, administered in four every-other-day injections
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard Glucantime therapy
Number of subjects: 89
Study: 2720865

Group type: EXPERIMENTAL
Intervention: Distilled water (group A, 24 patients)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Glycine 1.5 per cent (group B, 25 patients)
Number of subjects: 49
Study: 30547424

Group type: EXPERIMENTAL
Intervention: Telephone follow-up (1 to 14 days post-discharge)
Number of subjects: 863

Group type: COMPARATOR
Intervention: Clinical visit after discharge
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 863
Study: 28765032

Group type: EXPERIMENTAL
Intervention: Swaddling with oral administration of 0.2 ml of 24% sucrose
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Swaddling with oral administration of breast milk
Number of subjects: 87

Group type: COMPARATOR
Intervention: Swaddling with oral administration of distilled water (control)
Number of subjects: 87
Study: 26376345

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 30
Study: 22965458

Group type: EXPERIMENTAL
Intervention: Low-dose spinal anaesthesia (8-mg hyperbaric bupivacaine 0.5% with fentanyl 20 μg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 40
Study: 20856124

Group type: EXPERIMENTAL
Intervention: High-pitch scan mode (HPM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional pitch mode (CPM)
Number of subjects: 60
Study: 18845966

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (HIET): 9 participants exercised 3 d x wk(-1) at an intensity > lactate threshold (LT) and 2 d x wk(-1) <= LT
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise training (LIET): 11 participants exercised 5 d x wk(-1) at an intensity <= lactate threshold (LT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No-exercise training (Control): 7 participants maintained their existing levels of physical activity
Number of subjects: 27
Study: 17063068

Group type: EXPERIMENTAL
Intervention: Experienced tester (tester 1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inexperienced tester (tester 2)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ADAP test
Number of subjects: 43
Study: 12760315

Group type: EXPERIMENTAL
Intervention: Nutrient canals presence in hypertensive patients
Number of subjects: 215

Group type: COMPARATOR
Intervention: Nutrient canals presence in normotensive patients
Number of subjects: 215
Study: 9862848

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopic ligation (EL)
Number of subjects: 0
Study: 8554246

Group type: EXPERIMENTAL
Intervention: Intensive therapy with 3 or more daily insulin injections or continuous subcutaneous insulin infusion, guided by 4 or more glucose tests per day
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional therapy with 1 or 2 daily insulin injections
Number of subjects: 1441
Study: 1992534

Group type: EXPERIMENTAL
Intervention: 480 mg/d megestrol acetate
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 960 mg/d megestrol acetate
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Low-dose megestrol acetate
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate
Number of subjects: 55
Study: 6411382

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Topical cromoglycates
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61